These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 9640486

  • 1. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ, Carter BL.
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [Abstract] [Full Text] [Related]

  • 2. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
    Brogden RN, Markham A.
    Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
    [Abstract] [Full Text] [Related]

  • 3. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME, Kelly MW.
    Pharmacotherapy; 1998 Nov; 18(3):463-85. PubMed ID: 9620098
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Differential properties of mibefradil in hypertension and angina.
    Kobrin I.
    J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
    [Abstract] [Full Text] [Related]

  • 6. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
    Massie BM.
    Am J Hypertens; 1998 Apr; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
    Davies GJ, Tzivoni D, Kobrin I.
    Am J Cardiol; 1997 Aug 21; 80(4B):34C-39C. PubMed ID: 9286852
    [Abstract] [Full Text] [Related]

  • 9. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
    van der Vring JA, Daniëls MC, Holwerda NJ, Withagen PJ, Schelling A, Cleophas TJ, Hendriks MG.
    Angiology; 1999 Jun 21; 50(6):447-54. PubMed ID: 10378820
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
    Noll G, Lüscher TF.
    Cardiology; 1998 Jun 21; 89 Suppl 1():10-5. PubMed ID: 9570424
    [Abstract] [Full Text] [Related]

  • 13. Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.
    Davies GJ, Kobrin I, Caspi A, Reisin LH, de Albuquerque DC, Armagnijan D, Coelho OR, Schneeweiss A.
    Am Heart J; 1997 Aug 21; 134(2 Pt 1):220-8. PubMed ID: 9313601
    [Abstract] [Full Text] [Related]

  • 14. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
    Schneeweiss A, Kobrin I, Charlon V, Caspi A, Marmor A, Sclarovsky S, Reisin L, Schlesinger Z.
    Am Heart J; 1998 Feb 21; 135(2 Pt 1):272-80. PubMed ID: 9489976
    [Abstract] [Full Text] [Related]

  • 15. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris.
    Alpert JS, Kobrin I, DeQuattro V, Friedman R, Shepherd A, Fenster PE, Thadani U.
    Am J Cardiol; 1997 Apr 15; 79(8):1025-30. PubMed ID: 9114758
    [Abstract] [Full Text] [Related]

  • 16. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
    Massie BM, Lacourcière Y, Viskoper R, Woittiez A, Kobrin I.
    Am J Cardiol; 1997 Aug 21; 80(4B):27C-33C. PubMed ID: 9286851
    [Abstract] [Full Text] [Related]

  • 17. Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris.
    Frishman WH, Bittar N, Glasser S, Habib G, Smith W, Pordy R.
    Clin Cardiol; 1998 Jul 21; 21(7):483-90. PubMed ID: 9669057
    [Abstract] [Full Text] [Related]

  • 18. Diversity of calcium antagonists.
    Pitt B.
    Clin Ther; 1997 Jul 21; 19 Suppl A():3-17. PubMed ID: 9385501
    [Abstract] [Full Text] [Related]

  • 19. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist.
    Abernethy DR.
    Am J Cardiol; 1997 Aug 21; 80(4B):4C-11C. PubMed ID: 9286848
    [Abstract] [Full Text] [Related]

  • 20. Combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris: beneficial effect of calcium channel blockers largely determined by their effect on heart rate.
    Cleophas TJ, van der Sluijs J, van der Vring JA, Daniëls MC, Holwerda KJ, Withagen AJ, Schelling A, Hendriks MG, Zwinderman AH.
    J Clin Pharmacol; 1999 Jul 21; 39(7):738-46. PubMed ID: 10392329
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.